Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Sun Pharma & ICGEB to jointly develop dengue vaccine

The pharma company will fund & support further development of a vaccine candidate developed by International Centre for Genetic Engineering and Biotechnology (ICGEB)

BS B2B Bureau  |  Mumbai 

Sun Pharma & ICGEB to jointly develop dengue vaccine

The Mumbai-based pharmaceutical company will collaborate with International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop a vaccine, targeted against all the four serotypes of virus (DENV) that cause disease in humans. has developed a tailored recombinant virus-like-particle (VLP) based tetravalent vaccine, containing host-receptor binding domain of envelope protein of all the four DENV serotypes. has conducted pre-clinical studies over the past seven years and developed the existing know-how and patents for this candidate. 

This is the second collaboration between and focusing on dengue. The first one announced in May 2016 was related to the development of a botanical drug for treatment of dengue. The current collaboration is focussed on developing a novel, safe & effective for the prevention of dengue.

“Our new collaboration with for developing an affordable is part of our broader commitment for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world. Our decision to partner with on program followed extensive due diligence and expert consultations on existing programs globally,” said Kirti Ganorkar, executive VP & head, global business development, Sun Pharma.

Initial findings of ICGEB’s indicate that the candidate induces serotype-specific non-cross-reactive and strongly neutralising antibodies without disease enhancing concerns. These features of the candidate differentiate this development programme from other programs that are developed or in development globally. This development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population.

Dr Salunke, director, International Centre for Genetic Engineering and Biotechnology, added, “Despite recent approval of a and several candidates being at advance stage of clinical trials, the development of a safe, affordable and efficacious still faces major challenges. I am pleased that the development program led by Dr Navin Khanna at is now proceeding to clinical development phase with Sun Pharma. The initial support from DBT and subsequent funding from Wellcome Trust has enabled to bring this candidate at the stage it is today. Our pre-clinical data is very encouraging and this could be an ideal candidate for all target populations.”

As per the agreement, will fund & support further development of the candidate and existing know-how and patents. will grant exclusive rights and licenses for development and commercialisation of this globally. In turn, will receive pre-defined royalty & milestone payments. 

will set-up a advisory group to provide technical and regulatory support to the development programme. It will also be exclusively responsible for all regulatory filings for the product globally including, without limitation, CDSCO-India, WHO, USFDA, EMA, MHRA etc. The company will explore commercialisation opportunities to provide this to patients across India, emerging markets, Western Europe, Japan and USA at affordable costs post regulatory approvals in these markets. The immediate priority of this partnership is to complete the toxicology studies for further development of the program.

Sun Pharma, which invests over $ 300 million annually on research and development in and biologics, will use its in-house expertise as well as expertise of its associate company, ARTES Biotechnology GmbH, in development of vaccine. ARTES will add their experience and proprietary know-how in production of VLP based vaccines from yeast production cell lines. 

RECOMMENDED FOR YOU

Sun Pharma & ICGEB to jointly develop dengue vaccine

The pharma company will fund & support further development of a vaccine candidate developed by International Centre for Genetic Engineering and Biotechnology (ICGEB)

The pharma company will fund & support further development of a vaccine candidate developed by International Centre for Genetic Engineering and Biotechnology (ICGEB)
The Mumbai-based pharmaceutical company will collaborate with International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop a vaccine, targeted against all the four serotypes of virus (DENV) that cause disease in humans. has developed a tailored recombinant virus-like-particle (VLP) based tetravalent vaccine, containing host-receptor binding domain of envelope protein of all the four DENV serotypes. has conducted pre-clinical studies over the past seven years and developed the existing know-how and patents for this candidate. 

This is the second collaboration between and focusing on dengue. The first one announced in May 2016 was related to the development of a botanical drug for treatment of dengue. The current collaboration is focussed on developing a novel, safe & effective for the prevention of dengue.

“Our new collaboration with for developing an affordable is part of our broader commitment for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world. Our decision to partner with on program followed extensive due diligence and expert consultations on existing programs globally,” said Kirti Ganorkar, executive VP & head, global business development, Sun Pharma.

Initial findings of ICGEB’s indicate that the candidate induces serotype-specific non-cross-reactive and strongly neutralising antibodies without disease enhancing concerns. These features of the candidate differentiate this development programme from other programs that are developed or in development globally. This development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population.

Dr Salunke, director, International Centre for Genetic Engineering and Biotechnology, added, “Despite recent approval of a and several candidates being at advance stage of clinical trials, the development of a safe, affordable and efficacious still faces major challenges. I am pleased that the development program led by Dr Navin Khanna at is now proceeding to clinical development phase with Sun Pharma. The initial support from DBT and subsequent funding from Wellcome Trust has enabled to bring this candidate at the stage it is today. Our pre-clinical data is very encouraging and this could be an ideal candidate for all target populations.”

As per the agreement, will fund & support further development of the candidate and existing know-how and patents. will grant exclusive rights and licenses for development and commercialisation of this globally. In turn, will receive pre-defined royalty & milestone payments. 

will set-up a advisory group to provide technical and regulatory support to the development programme. It will also be exclusively responsible for all regulatory filings for the product globally including, without limitation, CDSCO-India, WHO, USFDA, EMA, MHRA etc. The company will explore commercialisation opportunities to provide this to patients across India, emerging markets, Western Europe, Japan and USA at affordable costs post regulatory approvals in these markets. The immediate priority of this partnership is to complete the toxicology studies for further development of the program.

Sun Pharma, which invests over $ 300 million annually on research and development in and biologics, will use its in-house expertise as well as expertise of its associate company, ARTES Biotechnology GmbH, in development of vaccine. ARTES will add their experience and proprietary know-how in production of VLP based vaccines from yeast production cell lines. 

image
Business Standard
177 22

Sun Pharma & ICGEB to jointly develop dengue vaccine

The pharma company will fund & support further development of a vaccine candidate developed by International Centre for Genetic Engineering and Biotechnology (ICGEB)

The Mumbai-based pharmaceutical company will collaborate with International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop a vaccine, targeted against all the four serotypes of virus (DENV) that cause disease in humans. has developed a tailored recombinant virus-like-particle (VLP) based tetravalent vaccine, containing host-receptor binding domain of envelope protein of all the four DENV serotypes. has conducted pre-clinical studies over the past seven years and developed the existing know-how and patents for this candidate. 

This is the second collaboration between and focusing on dengue. The first one announced in May 2016 was related to the development of a botanical drug for treatment of dengue. The current collaboration is focussed on developing a novel, safe & effective for the prevention of dengue.

“Our new collaboration with for developing an affordable is part of our broader commitment for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world. Our decision to partner with on program followed extensive due diligence and expert consultations on existing programs globally,” said Kirti Ganorkar, executive VP & head, global business development, Sun Pharma.

Initial findings of ICGEB’s indicate that the candidate induces serotype-specific non-cross-reactive and strongly neutralising antibodies without disease enhancing concerns. These features of the candidate differentiate this development programme from other programs that are developed or in development globally. This development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population.

Dr Salunke, director, International Centre for Genetic Engineering and Biotechnology, added, “Despite recent approval of a and several candidates being at advance stage of clinical trials, the development of a safe, affordable and efficacious still faces major challenges. I am pleased that the development program led by Dr Navin Khanna at is now proceeding to clinical development phase with Sun Pharma. The initial support from DBT and subsequent funding from Wellcome Trust has enabled to bring this candidate at the stage it is today. Our pre-clinical data is very encouraging and this could be an ideal candidate for all target populations.”

As per the agreement, will fund & support further development of the candidate and existing know-how and patents. will grant exclusive rights and licenses for development and commercialisation of this globally. In turn, will receive pre-defined royalty & milestone payments. 

will set-up a advisory group to provide technical and regulatory support to the development programme. It will also be exclusively responsible for all regulatory filings for the product globally including, without limitation, CDSCO-India, WHO, USFDA, EMA, MHRA etc. The company will explore commercialisation opportunities to provide this to patients across India, emerging markets, Western Europe, Japan and USA at affordable costs post regulatory approvals in these markets. The immediate priority of this partnership is to complete the toxicology studies for further development of the program.

Sun Pharma, which invests over $ 300 million annually on research and development in and biologics, will use its in-house expertise as well as expertise of its associate company, ARTES Biotechnology GmbH, in development of vaccine. ARTES will add their experience and proprietary know-how in production of VLP based vaccines from yeast production cell lines. 

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard